Table 1.

Clinical Characteristics of the Patients Studied

Characteristics No. % Mean ± 1 SD
Total 145  100  
Gender  
 Male  85  59  
 Female 60  41  
Age (median, 35 yr; range, 16-75 yr)  
 15-19 17  12  
 20-29  43  29  
 30-39  27  19 
 40-49  27  19  
 50-59  10  7  
 60-69  17 11  
 70-75  4  3  
Histology  
 Lymphocyte predominance  2  1  
 Nodular sclerosis  68  46 
 Lymphocyte depleted nodular sclerosis  20  14  
 Mixed cellularity  42  30  
 Lymphocyte depletion  13  
Stage  
 II B  45  31  
 III2 A  22 15  
 III B  39  27  
 IV A  11  8  
 IV B 28  19  
Mediastinal bulk  47  32  
Spleen involvement 29  20  
Extranodal involvement  
 Bone marrow  22 15  
 Lung  9  6  
 Liver  6  4  
 Other visceral organs  3  2  
Hb <100 g/L  16  11 119 ± 20  
ESR >40 mm 1st hour  95  66 61.6 ± 37.6  
Serum LDH >450 U/L  33  23 400 ± 225  
Serum albumin <30 g/dL  26  18 3.64 ± 0.59  
SNLG prognostic index >0.5  52  36 0.39 ± 0.2  
IDHD probability of surviving at 5 yr   0.71 ± 0.18 
Characteristics No. % Mean ± 1 SD
Total 145  100  
Gender  
 Male  85  59  
 Female 60  41  
Age (median, 35 yr; range, 16-75 yr)  
 15-19 17  12  
 20-29  43  29  
 30-39  27  19 
 40-49  27  19  
 50-59  10  7  
 60-69  17 11  
 70-75  4  3  
Histology  
 Lymphocyte predominance  2  1  
 Nodular sclerosis  68  46 
 Lymphocyte depleted nodular sclerosis  20  14  
 Mixed cellularity  42  30  
 Lymphocyte depletion  13  
Stage  
 II B  45  31  
 III2 A  22 15  
 III B  39  27  
 IV A  11  8  
 IV B 28  19  
Mediastinal bulk  47  32  
Spleen involvement 29  20  
Extranodal involvement  
 Bone marrow  22 15  
 Lung  9  6  
 Liver  6  4  
 Other visceral organs  3  2  
Hb <100 g/L  16  11 119 ± 20  
ESR >40 mm 1st hour  95  66 61.6 ± 37.6  
Serum LDH >450 U/L  33  23 400 ± 225  
Serum albumin <30 g/dL  26  18 3.64 ± 0.59  
SNLG prognostic index >0.5  52  36 0.39 ± 0.2  
IDHD probability of surviving at 5 yr   0.71 ± 0.18 
Close Modal

or Create an Account

Close Modal
Close Modal